-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BY6Tb8jLpdr+0vulRBcFX1Ihdx9qU2uyfGHbBYFz8A+80bdXI65qQNT0em9xtlZn f8NwkzI1m7Q0lplBTyxzkg== 0001104659-05-034142.txt : 20050726 0001104659-05-034142.hdr.sgml : 20050726 20050726160223 ACCESSION NUMBER: 0001104659-05-034142 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20050726 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20050726 DATE AS OF CHANGE: 20050726 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERIT MEDICAL SYSTEMS INC CENTRAL INDEX KEY: 0000856982 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870447695 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-18592 FILM NUMBER: 05974285 BUSINESS ADDRESS: STREET 1: 1600 WEST MERIT PARK WAY CITY: SOUTH JORDAN STATE: UT ZIP: 84095 BUSINESS PHONE: 8012531600 MAIL ADDRESS: STREET 1: 1600 WEST MERIT PARKWAY CITY: SOUTH JORDAN STATE: UT ZIP: 84095 8-K 1 a05-13555_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC  20549

 


 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported):  July 26, 2005

 

Merit Medical Systems, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Utah

 

0-18592

 

87-0447695

(State or other jurisdiction of
incorporation or organization)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

 

 

 

 

1600 West Merit Parkway
South Jordan, Utah

 

84095

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

 

 

 

Registrant’s Telephone Number, Including Area Code:

(801) 253-1600

 

 

 

 

 

N/A

(Former name, former address, and formal fiscal year, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b)  under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c)  under the Exchange Act (17 CFR 240.13e-4(c)

 

 



 

Item 2.02   Results of Operations and Financial Condition .

 

On July 26, 2005, Merit Medical Systems, Inc. (“Merit”) issued a press release announcing its financial results for the quarter ended June 30, 2005. The full text of Merit’s press release, together with related unaudited financial statements, is furnished herewith as Exhibit 99.1.

 

The information in this Current Report on Form 8-K (including the exhibit) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01.         Financial Statements and Exhibits

 

(c)                        Exhibits

 

99.1         Press Release Issued by Merit Medical Systems, Inc., dated July 26, 2005, entitled “Merit Medical Systems Reports Record Revenues for Second Quarter 2005,” together with related unaudited financial statements.

 

Forward-Looking Statements

 

Statements contained in this release which are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2004. Such risks and uncertainties include, market acceptance of new products, introduction of products in a timely fashion, product recalls, delays in obtaining regulatory approvals, or the failure to maintain such approvals, cost increases, fluctuations in and obsolescence of inventory, price and product competition, availability of labor and materials, development of new products and technology that could render the Company’s products obsolete, product liability claims, modification or limitation of governmental or private insurance reimbursement, infringement of our technology or the assertion that our technology infringes the rights of other parties, foreign currency fluctuations, challenges associated with the Company’s growth strategy, changes in health care markets related to healthcare reform initiatives, litigation and other factors referred to in the Company’s 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

Merit Medical Systems, Inc.

 

 

 

 

Dated: July 26, 2005

By:

/s/ Kent W. Stanger

 

 

 

Kent W. Stanger, Chief Financial Officer,

 

 

Secretary and Treasurer

 

3



 

EXHIBIT INDEX

 

EXHIBIT
NUMBER

 

DESCRIPTION

 

 

 

99.1

 

Press Release Issued by Merit Medical Systems, Inc., dated July 26, 2005, entitled “Merit Medical Systems Reports Record Revenues for Second Quarter 2005,” together with related unaudited financial statements.

 

4


EX-99.1 2 a05-13555_1ex99d1.htm EX-99.1

Exhibit 99.1

 

1600 West Merit Parkway South Jordan, UT  84095

Telephone:  801-253-1600 Fax:  801-253-1688

PRESSRELEASE

 

FOR IMMEDIATE RELEASE

 

Date:

 

July 26, 2005

Contact:

 

Anne-Marie Wright, Director of Corporate Communications

Phone:

 

(801) 208-4167

E-mail: awright@merit.com

Fax: (801) 253-1681

 

MERIT MEDICAL SYSTEMS REPORTS RECORD REVENUES
FOR SECOND QUARTER 2005

 

SOUTH JORDAN, UTAH— Merit Medical Systems, Inc. (NASDAQ:NMS:MMSI), a leading manufacturer and marketer of proprietary disposable accessories used primarily in cardiology and radiology procedures, today reported net income of $4.7 million, or $0.17 per share, on record revenues of $42.4 million, up 9% for its quarter ended June 30, 2005. For the comparable quarter of 2004, the Company reported net income of $5.1 million, or $0.18 per share, on revenues of $38.9 million.

 

Revenues for the six-month period ended June 30, 2005 were a record $82.7 million, compared with $76.6 million for the same six-month period in 2004, a gain of 8%. Net income for the six-month period ended June 30, 2005 was $8.8 million, or $0.32 per share, compared with $9.4 million, or $0.34 per share in the same period of 2004.

 

All product categories of Merit’s business contributed to revenue growth in the second quarter of 2005, with catheter sales increasing 22%, custom kit sales rising 8%, inflation device sales growing 5%, and stand-alone device sales going up 3%, compared to the second quarter of 2004. Procedure trays, a new category, contributed 1.8% to sales in the second quarter of 2005.

 

For the six-month period ended June 30, 2005, the Company’s total sales grew 8%, with catheter sales increasing 14%, custom kit sales rising 7%, inflation device sales growing 5%, and stand-alone device sales going up 4%, compared to the six-month period ended June 30, 2004. Procedure trays, a new category, contributed 1.6% to sales in the first six months of 2005.

 

“We are pleased to report record sales for the second quarter, as we move forward with investments in new facilities, products and sales personnel,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “We launched two significant products during the second quarter – the Prelude™ sheath introducer and the Viceroy™ inflation device – and are on schedule to introduce five additional products by the end of the year. The completion of our 2005 goals will help to accelerate our revenues and opportunities in the future.”

 

Gross margins were down to 43.1% of sales in the second quarter of 2005 from 46.3% of sales in the second quarter of 2004, due primarily to Merit’s new procedure tray business in Richmond, Virginia, as well as new

 

1



 

facilities and an associated increase in overhead. Gross margins for the first six months of 2005 were 43.2% of sales, a decrease from 45.0% of sales for the comparable period of 2004.

 

Selling, general and administrative expenses for the second quarter of 2005 were 22.0% of sales, compared with 22.6% of sales in the previous year’s second quarter. Research and development costs during the second quarter of 2005 were 4.1% of sales, compared with 3.3% of sales for the same period last year. Income from operations for the second quarter ended June 30, 2005 was $7.2 million, compared to $7.9 million for the same period of 2004, a decrease of 9%, which can be attributed to an increase in R&D costs and additional staff and expenses to support the launch of new products.

 

For the six-month period ended June 30, 2005, selling, general and administrative expenses were 23.0% of sales, compared with 22.6% of sales for the first six months of 2004. Research and development costs were 4.0% of sales for the first six months of 2005, compared to 3.2% of sales for the same period of 2004. Income from operations for the first six months of 2005 was $13.4 million, compared to $14.6 million for the same period of 2004, a decrease of 9%.

 

Merit’s effective tax rates for the second quarter and the six-month period ended June 30, 2005 were 36.0%, compared with 37.2% and 37.0%, respectively, for the comparable periods of 2004.

 

The Company’s cash on hand was $18.8 million as of June 30, 2005. This cash balance is net of $9.9 million spent during the three months ended June 30, 2005 on building expansions in South Jordan, Utah and Richmond, Virginia.

 

2



 

INCOME STATEMENT

(Unaudited, in thousands except per share data)

 

 

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

 

 

 

2005

 

2004

 

2005

 

2004

 

 

 

 

 

 

 

 

 

 

 

SALES

 

$

42,405

 

$

38,921

 

$

82,679

 

$

76,583

 

 

 

 

 

 

 

 

 

 

 

COST OF SALES

 

24,145

 

20,912

 

46,957

 

42,141

 

 

 

 

 

 

 

 

 

 

 

GROSS PROFIT

 

18,260

 

18,009

 

35,722

 

34,442

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

9,326

 

8,796

 

19,033

 

17,332

 

Research and development

 

1,747

 

1,273

 

3,294

 

2,465

 

Total

 

11,073

 

10,069

 

22,327

 

19,797

 

 

 

 

 

 

 

 

 

 

 

INCOME FROM OPERATIONS

 

7,187

 

7,940

 

13,395

 

14,645

 

 

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSE)

 

 

 

 

 

 

 

 

 

Litigation settlement

 

 

 

 

 

 

 

100

 

Interest income

 

143

 

133

 

325

 

256

 

Miscellaneous income (expense)

 

(20

)

7

 

(41

)

(9

)

Total Other Income - net

 

123

 

140

 

284

 

347

 

 

 

 

 

 

 

 

 

 

 

INCOME BEFORE INCOME TAX EXPENSE

 

7,310

 

8,080

 

13,679

 

14,992

 

 

 

 

 

 

 

 

 

 

 

INCOME TAX EXPENSE

 

2,629

 

3,008

 

4,923

 

5,545

 

 

 

 

 

 

 

 

 

 

 

NET INCOME

 

$

4,681

 

$

5,072

 

$

8,756

 

$

9,447

 

 

 

 

 

 

 

 

 

 

 

EARNINGS PER SHARE-

 

 

 

 

 

 

 

 

 

Basic

 

$

0.18

 

$

0.19

 

$

0.33

 

$

0.36

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$

0.17

 

$

0.18

 

$

0.32

 

$

0.34

 

 

 

 

 

 

 

 

 

 

 

AVERAGE COMMON SHARES-

 

 

 

 

 

 

 

 

 

Basic

 

26,725,684

 

26,301,004

 

26,616,813

 

26,183,069

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

27,726,579

 

27,729,654

 

27,658,419

 

27,754,410

 

 

3



 

BALANCE SHEET

(Unaudited in thousands)

 

 

 

June 30,
2005

 

December 31,
2004

 

ASSETS

 

 

 

 

 

Current Assets

 

 

 

 

 

Cash and cash equivalents

 

$

18,835

 

$

33,037

 

Trade receivables, net

 

21,199

 

19,724

 

Employee receivables

 

114

 

94

 

Other receivables

 

253

 

63

 

Inventories

 

26,715

 

23,096

 

Prepaid and other assets

 

1,243

 

797

 

Deferred income tax assets

 

41

 

56

 

Total Current Assets

 

68,400

 

76,867

 

 

 

 

 

 

 

Property and equipment, net

 

74,385

 

52,492

 

Other intangibles, net

 

2,758

 

1,990

 

Goodwill

 

5,738

 

5,570

 

Other assets

 

1,980

 

1,822

 

Note receivable

 

 

 

1,000

 

Deposits

 

156

 

136

 

Total Assets

 

$

153,417

 

$

139,877

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current Liabilities

 

 

 

 

 

Current portion of long-term debt

 

$

4

 

$

7

 

Trade payables

 

13,054

 

10,728

 

Accrued expenses

 

8,651

 

8,467

 

Advances from employees

 

274

 

221

 

Deferred income tax liabilities

 

503

 

227

 

Income taxes payable

 

1,578

 

2,273

 

Total Current Liabilities

 

24,064

 

21,923

 

 

 

 

 

 

 

Deferred income tax liabilities

 

2,365

 

2,580

 

Long-term debt

 

5

 

5

 

Deferred compensation payable

 

2,064

 

1,702

 

Deferred credits

 

2,510

 

2,615

 

Other liabilities

 

125

 

 

 

Total Liabilities

 

31,133

 

28,825

 

 

 

 

 

 

 

Stockholders’ Equity

 

 

 

 

 

Common stock

 

45,027

 

42,559

 

Retained earnings

 

77,647

 

68,891

 

Accumulated other comprehensive loss

 

(390

)

(398

)

Total stockholders’ equity

 

122,284

 

111,052

 

 

 

 

 

 

 

Total Liabilities and Stockholders’ Equity

 

$

153,417

 

$

139,877

 

 

4



 

CONFERENCE CALL

 

Merit Medical invites all interested parties to join its officers in its second quarter earnings conference call to be held today, July 26, 2005, at 5:00 p.m. Eastern (4:00 p.m. Central; 3:00 p.m. Mountain; and 2:00 p.m. Pacific). The telephone numbers to call are: (domestic) 800-240-5318 and (international) 303-262-2141.

 

A live webcast as well as a rebroadcast of the conference call will be available at www.merit.com and www.fulldisclosure.com. To listen to the live broadcast, please enter the site 10-15 minutes prior to the call in order to download any necessary media players. To access the webcast, click on the “CCBN Webcast” logo on the lower right-hand corner of Merit’s home page. The webcast will be archived on both sites. There is no other replay access to the call.

 

ABOUT MERIT

 

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical accessories used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 80 individuals. Merit employs approximately 1,440 people worldwide, with manufacturing facilities in Salt Lake City and South Jordan, Utah; Santa Clara, California; Angleton, Texas; Richmond, Virginia; Maastricht, The Netherlands; and Galway, Ireland.

 

Statements contained in this release which are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2004. Such risks and uncertainties include market acceptance of new products, introduction of products in a timely fashion, product recalls, delays in obtaining regulatory approvals, or the failure to maintain such approvals, cost increases, fluctuations in and obsolescence of inventory, price and product competition, availability of labor and materials, development of new products and technology that could render our products obsolete, product liability claims, modification or limitation of governmental or private insurance reimbursement, infringement of our technology or the assertion that our technology infringes the rights of other parties, foreign currency fluctuations, challenges associated with the Company’s growth strategy, changes in health care markets related to health care reform initiatives, litigation and other factors referred to in the Company’s 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.

 

# # #

 

5


GRAPHIC 3 g135551moimage002.gif GRAPHIC begin 644 g135551moimage002.gif M1TE&.#EA2@$P`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+`$``0!(`2X`@`````````+_C(^IR^T&HIRTVHNSWKS[#X;B2);A M@Z;J8K;N"\?R3,?KC3?USO?^#WSEAL2@\8A,*DO$YFT)C4JG/J<5U4IDAI2< MYLK`*"[<;LJCY>@ZK&^@4I0@)G/Y@1YFCN'Q2),,EF?VYD>(9[AQ9[>U![C( MJ`C0"&A8!R?F)4D(85;H.9@VLG98IME'&FB)U[D*PHF8J/HX2^H&:W?[>>F' M>F::"PHIZRJ(6W8%FCK,V:KKJBD2*6=Q*^W&!^PL:8J]4FC=G=T6/?K]!]:K MS,Q+W?R\3NP^+:\&FTW7SF[N.QDNWO_!0;),@8RI@P=O'C11"T55RL4L(9N' M;+K@,XCEET2,_YA"$2N'3..??0=9[0*'IJ%#;9\VUJ.U!9L_@2*%N11YSV:C MD#A+'?3HV) MC+Z:QH4KU._=H5T1YS7IKO+1K:,B`@.,]BT5MF.7U-+^CF M?ZO7;03M6"!KNH8M_\V:T.[AN';S0;)5;'-K1S*7%\8,4VZ>QR1SXQT('%%G MT\6K?GGID.)@Y]#S7H^._GSCT3.S/VQCM7OWB[#)F0W*O+R^YX?(D_^>L]M5 MIYU757:I%1B*?,6,]YT)K^#FWWT0@K=:A+^Q$"!.`[8%F8&J(6B)@AEN$X10 M%DIH(8%BC75B>X%-X=YV\*TG(G4J9H%B?O3T%=!GF[2('8"H);;AAC&^M\=Z MWKFHXP\F,@AE>A"A(0Y8Z-56FHW487G=D8*LP=>!0?IHQ(,M*A?E?O71-^%_ M'$+AY20R[E8C:K?1X-F9;>;HVF]`IH/4D-5]Y%N''HI9().*ZD?B5,GM*>6) M;1.>J*N.AA)'N:*M-I/Y\N.6:J M7?[)9ZE]T=:D?=8MB-U97.:DVQGS#8N0<,#_TFH>7FBN^15G@/$Z2!8<8BBH MAKT**)T63AV[Z&3:+2M<1V&Y2"Z2QS7WZIO(S?FB%#0-IPZZ2G[8+%EO3&M: M)X56^F*\/3*6+16BT0NKO:+5:B4^>ZDI1*&\*.?N$8'>D6'&206X,%^<*CPK MOJ>J2F+%H;V$ILDE%FPP51YGU6Z88E:I:B5X=ODD*S?39H.^XI)(LK!AZ1*+( ME*+Z2"EBRB[X,;(RBTR>V@TKW6B$=J_*W[:_LLM2<+L`VBVRX+H544@H=IZ!:6E92XB.J533`]>);=;
-----END PRIVACY-ENHANCED MESSAGE-----